Sevoflurane Sedation in Patients With Septic Shock (SSiS)
Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock
Sponsor: Kantonsspital Münsterlingen
Listed as NCT03643367, this PHASE2 trial focuses on Shock, Septic and remains actively recruiting participants. Sponsored by Kantonsspital Münsterlingen, it has been updated 11 times since 2026, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Not Yet Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 6 earlier versions
-
Jan 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2022 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2019 — Dec 2020 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2018 — Nov 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kantonsspital Münsterlingen
- Triemli Hospital
- University of Zurich
- Waid City Hospital, Zurich
For direct contact, visit the study record on ClinicalTrials.gov .